reports
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Phar...
- Jacob Mekhael
Zealand Pharma CMD key takeaways
Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital i...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
- Mathijs Geerts Danau
Zealand Pharma Announces Metabolic Frontier 2030 strategy, and agreeme...
Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a g...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research si...
Zealand Pharma and OTR Therapeutics enter multi-program strategic coll...
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets...
- Jacob Mekhael
- Thibault Leneeuw
- Jacob Mekhael
MaaT Pharma Final Xervyteg phase 3 data confirm strong survival outcom...
MaaT reported the final results from the phase 3 (ARES) trial of Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD at the American Society of Hematology (ASH) conference, being held 6-9 December 2025. The final OS results from the phase 3 (ARES) trial of MaaT013 coming in at 54% at 1 year confirm the previously reported 54% probability of survival that was shared with the topline readout in January 2025. We believe this brings a significant benefit vs. the 15% 1-year OS reported...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 5, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received i...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List How to start 2026?
How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...
EVS EVS BROADCAST EQUIPMENT SA
DIE D'IETEREN SA
SOF SOFINA SA
ASM ASM INTERNATIONAL N.V.
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism. Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET)Venue: Goldman...
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Hoste
- Jacob Mekhael
MaaT Pharma Model update post € 9.1m capital raise
MaaT announced the completion of a capital raise of € 9.1m (at a 9% discount to closing price prior to deal announcement), and expects to use the net proceeds of € 8.7m to fund Xervyteg commercialisation preparation in Europe, advance MaaT033 development, and prepare for a pivotal US study of Xervyteg in 2026. This capital raise unlocks a € 6m EIB tranche, extending the company's cash runway to August 2026. Upon anticipated EU approval of Xervyteg in mid-2026, MaaT is eligible to receive a € 12m...
- Mathijs Geerts Danau
MaaT Pharma Launches capital increase for gross proceeds of € 9m ...
MaaT announced the launch of a capital increase through a private placement with qualified investors and retail investors. The company intends to raise € 9m, the funds will extend the runway to summer 2026 (previously February 2026). MaaT plans to use the proceeds to fund the company's development and commercialization of Xervyteg. Trading will be suspended until at least November 14 after market close. We view this raise as a positive and reiterate our BUY rating and € 17 TP.
- Hilde Van Boxstael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Lewi
- Mathijs Geerts Danau
Zealand Pharma Uneventful 3Q25 results, upcoming CMD in December 2025
Zealand reported 3Q25 results and provides a business update which are in line with expectations. We note that dapiglutide development has been paused but that most important timelines have been reiterated. For the remainder or this year we do not expect big readouts, but look forward to the CMD in December. DKK 1,120 TP and BUY rating reiterated.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Zealand Pharma Announces Financial Results for the First Nine Months o...
Zealand Pharma Announces Financial Results for the First Nine Months of 2025 Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026. Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way for 42-week topline...
Zealand Pharma to participate in the Jefferies Global Healthcare Confe...
Zealand Pharma to participate in the Jefferies Global Healthcare Conference Press release – No. 16 / 2025 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 12, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 10:30am GMT (11:30am CET) on Wednesday, November 19, 2025. A ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.